Genetic testing of mammary gland carcinoma

Targeted drug screening: Targeted drugs specifically act on confined gene mutation loci to promote the apoptosis of tumor cells, while have no adverse effects on the normal tissues and cells around the cancer lesions. Monitoring and analysis targeting drug-related gene mutation status in the tumor tissues or blood of breast cancer patients via multiple gene testing technique, will assist doctors to screen for the best target drugs that patients are most likely to benefit from them.

Assessment of the toxic side effects of chemotherapy: The intrinsic drug metabolism and clearance capacity of patients directly determine the effectiveness of chemotherapy agents and the strength of their side effects. Detection and analysis gene mutation status associated with targeting drug metabolism and removal machinery of breast cancer patients through multiple gene testing technique, will indicate chemotherapy efficacy and the side effects for patients and lead to more reasonable choice of chemotherapy drugs by doctors and patients.

Classification of patients in clinical trial: There are 6 FDA approved targeted drugs for breast cancer so far. More medication reagents are in the clinical trial pipelines. Detection and analysis whether the breast cancer patients are carriers of associated genes for the ongoing clinical trial medicines or of beneficial effects of other drugs through multiple gene detection platform, will surely maximize the medication benefit for breast cancer patients.

Detection of drug resistance: Though the application of small molecular targeted drugs significantly improves the outcome of prognosis, the inevitable primary and secondary drug resistance become a serious barrier to further improve the clinical benefits for patients. Multiple mutation detection of multiple genes at once, together with synchronization analysis of sensitive mutation and drug resistance mutations through multiple gene testing technique, will assist doctors to select the most appropriate treatment plan.

Genetic Risk: Each person with a unique genetic background, their oncogenic risk is correspondingly different. Certain population are tumor susceptibility gene mutations carriers and have a much higher risk to suffering breast cancer, or other common gynecological tumors than non-carriers, and this susceptibility can be transferred from parents to their next generation. So detection whether breast cancer patients are carrying tumor susceptibility gene mutations and genetic correlation analysis of tumors in patients suffering from breast cancer, will clearly point out if their immediate kin has a high risk for similar malignancy, so that specific preventive measures will be adopted to avoid the disease development.